Edesa Biotech (EDSA) Financials

Edesa Biotech’s latest quarter shows a company still operating at a meaningful loss, but with a stronger cash position than a year ago and enough liquidity to keep funding its research pipeline for now.

For Q2 2026, Edesa reported no revenue and a net loss of $4.2 million, compared with a loss of $2.2 million in Q1 2026 and $1.7 million in Q2 2025. Operating expenses also rose sharply quarter over quarter, driven by higher R&D and SG&A spending. That said, the balance sheet shows $10.0 million in cash and equivalents at March 31, 2026, up from $1.6 million a year earlier, reflecting the company’s continued reliance on equity financing.

Key trends over the last several quarters:

• Cash increased significantly year over year. Cash and equivalents rose to $10.0 million in Q2 2026 from $1.6 million in Q1 2025, giving the company more runway than it had last year.
• Equity financing has boosted liquidity. The company raised cash through common and preferred share issuance in recent quarters, helping offset operating losses.
• Operating cash outflow improved from the prior quarter. Net cash used in operating activities was $2.0 million in Q2 2026 versus $2.1 million in Q1 2026 and $2.4 million in Q2 2025.
• Accounts payable remains a meaningful source of short-term funding. Current liabilities are modest relative to assets, and payables have helped support working capital management.
• Revenue remains at zero. Edesa has not yet generated sales, so the business is still entirely dependent on financing and potential clinical or partnership milestones.
• Other income continues to help offset losses. Interest and other income contributed modestly, but it is not enough to materially change the earnings profile.
• Share count has risen over time. Weighted average diluted shares increased from prior periods, which can dilute future per-share value if additional equity is issued.
• Intangible assets remain a large balance sheet item. These assets likely reflect development-related value, but they do not provide near-term cash generation.
• Losses widened sharply in Q2 2026. Net loss grew to $4.2 million from $2.2 million in Q1 2026, indicating a heavier burn rate.
• Operating expenses are climbing. Q2 2026 operating expenses totaled $4.3 million, up from $2.3 million in Q1 2026, driven by higher R&D and SG&A.
• The company remains cash-burning. Despite a stronger balance sheet, Edesa is still consuming cash each quarter and will likely need additional funding if losses continue.
• Balance sheet equity has been volatile. Total common equity fell sharply from $14.0 million in Q1 2026 to $1.8 million in Q2 2026, underscoring the instability of the capital structure.

Bottom line: Edesa Biotech ended Q2 2026 with more cash than it has had in years, but the company is still pre-revenue and burning cash at a significant rate. For retail investors, the key questions remain whether its pipeline can generate a value-creating catalyst before another financing round is needed and whether rising operating costs can be controlled.